Innate Pharma (IPHA) Return on Sales (2019 - 2025)
Historic Return on Sales for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to 8.07%.
- Innate Pharma's Return on Sales fell 51500.0% to 8.07% in Q2 2025 from the same period last year, while for Jun 2025 it was 1.31%, marking a year-over-year decrease of 13100.0%. This contributed to the annual value of 0.0% for FY2022, which is 2900.0% up from last year.
- Per Innate Pharma's latest filing, its Return on Sales stood at 8.07% for Q2 2025, which was down 51500.0% from 3.6% recorded in Q4 2024.
- Innate Pharma's 5-year Return on Sales high stood at 0.02% for Q2 2023, and its period low was 8.07% during Q2 2025.
- Its 5-year average for Return on Sales is 1.77%, with a median of 0.6% in 2021.
- Its Return on Sales has fluctuated over the past 5 years, first soared by 6100bps in 2022, then tumbled by -51500bps in 2025.
- Quarter analysis of 5 years shows Innate Pharma's Return on Sales stood at 0.61% in 2021, then surged by 100bps to 0.0% in 2022, then plummeted by 2000000000bps to 0.11% in 2023, then crashed by -3162bps to 3.6% in 2024, then tumbled by -124bps to 8.07% in 2025.
- Its Return on Sales stands at 8.07% for Q2 2025, versus 3.6% for Q4 2024 and 2.92% for Q2 2024.